Learn More About the 2026 Summit
Sinai Health: How Blood-Based IBD Biomarkers Are Redefining the Future of Precision Medicine in IBD
Recent research from Sinai Health has revealed a compelling breakthrough in inflammatory bowel disease (IBD): a simple blood test may be able to predict Crohn’s disease years before symptoms appear.
How AbbVie and Takeda Shape Precision IBD on AI and Combination Therapies
As the complexity and heterogeneity of Crohn’s disease and ulcerative colitis become increasingly clear, biopharma leaders are moving beyond monotherapy toward more precise, data-driven development approaches.
Explore the Agenda
Discover cutting-edge sessions on AI, biomarkers, and combination therapies redefining IBD precision medicine.
Partner With Us
Connect with senior biopharma leaders seeking innovative tools, models, and data solutions to advance IBD pipelines.
Join Biopharma Experts
Network with industry pioneers shaping the next generation of personalized Crohn’s and Colitis treatments.